Company / Cash & Equivalents
Anixa Biosciences Inc Cash & Equivalents History
FY2014-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.3M
FY2024
5-year range
$915.0K / $12.4M
FY2020-FY2024
Trend
+38.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $898,172 in FY2014 to $12M in FY2022.
Based on SEC 10-K filings.
$1M in FY2024 with a 10-year CAGR of +3.5%.
Declined from $12M to $1M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -16.1%
- 10-Year CAGR
- +3.5%
Key checks
Key Insights
- 5-year CAGR of -16.1%, indicating a declining trend.
- In FY2024, cash & equivalents increased 38.9% year-over-year.
- Peak cash & equivalents was recorded in FY2022.
- Lowest cash & equivalents in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.3M | +38.9% |
| FY2023 | $915.0K | -92.6% |
| FY2022 | $12.4M | +92.6% |
| FY2020 | $6.4M | +110.0% |
| FY2019 | $3.1M | -8.5% |
| FY2018 | $3.3M | +34.2% |
| FY2017 | $2.5M | -43.0% |
| FY2016 | $4.4M | +30.0% |
| FY2015 | $3.4M | +274.2% |
| FY2014 | $898.2K | +16.0% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026